Following on from a decision by the Indian Patent Office to grant a compulsory licence for Sorafenib Tosylate, the country’s first,  against Bayer’s Nexavar, a first-line treatment for liver and kidney cancer, the government of fellow Asian nation Indonesia has taken the unprecedented step of overriding the patents on seven HIV and hepatitis treatments, citing urgent need to improve patient access.

Tags Bayer Compulsory Licence Nexavar